Compare CRNX & MHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | MHO |
|---|---|---|
| Founded | 2008 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2018 | 1995 |
| Metric | CRNX | MHO |
|---|---|---|
| Price | $33.65 | $118.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $74.78 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 1.0M | 188.2K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 14.74 |
| Revenue | $1,039,000.00 | ★ $4,417,781,000.00 |
| Revenue This Year | $722.66 | $0.66 |
| Revenue Next Year | $183.79 | $6.97 |
| P/E Ratio | ★ N/A | $8.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.10 | $100.22 |
| 52 Week High | $57.99 | $158.92 |
| Indicator | CRNX | MHO |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 27.65 |
| Support Level | $33.23 | $118.03 |
| Resistance Level | $37.23 | $121.55 |
| Average True Range (ATR) | 1.62 | 3.38 |
| MACD | 0.13 | -0.82 |
| Stochastic Oscillator | 8.33 | 6.85 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.